Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06141265 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

Study acronym: BRAND
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Sep 2026 → Mar 2027
See other at-risk trials from Peking University Cancer Hospital & Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Peking University Cancer Hospital & Institute to Peking University Cancer Hospital & Institute
    • Primary completion pushed from Sep 2026 to Mar 2027
    • Study completion pushed from Sep 2027 to Dec 2028
    • Eligibility criteria expanded, about 18 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, open-label, single-arm phase II clinical trial investigating the efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly diagnosed advanced epithelial ovarian cancer (EOC), including primary peritoneal and/or fallopian tube tumors, following response to front-line chemotherapy in combination with bevacizumab. A total of 116 patients will be enrolled.
Trial Details
NCT Number NCT06141265
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions
(from sponsor)		 Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov